MLKL and cardiomyopathy: There are a number of other drugs that can exert a therapeutic effect by inhibiting necroptosis, such as ursolic acid in intestinal ischemia–reperfusion injury via STAT3 signaling [260] and rapamycin in doxorubicin-induced cardiomyopathy via the RIPK3-MLKL pathway, whose PTMs need to be explored and identified [261].